Nkarta, Inc. (NKTX)

5,26 -0,59 (-10,09%) Börsenschluss: 04:00PM EDT

Nkarta, Inc.

1150 Veterans Boulevard
South San Francisco, CA 94080
United States
(925) 407-1049
https://www.nkartatx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 150

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Paul J. Hastings	CEO, President & Director	935,18k	N/A	1960
Ms. Alyssa Levin C.A., CPA	Chief Financial & Business Officer and Principal Accounting Officer	762,4k	N/A	1985
Dr. David R. Shook M.D.	Chief Medical Officer	631,55k	N/A	1978
Dr. Ralph Brandenberger Ph.D.	Chief Technical Officer	N/A	N/A	1969
Dr. James Trager Ph.D.	Chief Scientific Officer	N/A	N/A	1963
Mr. Greg Mann	Vice President of Public Affairs and Investor Relations	N/A	N/A	N/A
Dr. Alicia J. Hager	Chief Legal Officer & Corporate Secretary	590,94k	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Corporate Governance

Nkarta, Inc.s ISS Governance QualityScore, Stand 1. Juli 2024, lautet 7. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 5, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.